TOP > News Release > Products
- Guide to Category Symbols
Corporate
R&D
Products
Others
2008
-
- FOREST LABORATORIES, INC. AND DAIICHI SANKYO, INC. ANNOUNCE
THE TERMINATION OF THE AZOR CO-PROMOTION AGREEMENT - FOREST LABORATORIES, INC. AND DAIICHI SANKYO, INC. ANNOUNCE
-
- Welchol(R) Added to the American College of Endocrinology/American Association of Clinical Endocrinologists "Road Maps to Achieve Glycemic Control in Patients with Type 2 Diabetes Mellitus"
-
- The Percutaneous Absorption-Type Analgesic and Anti-inflammatory Drug Loxonin(R)Tape 50mg/100mg
Receives Approval for Manufacture and Marketing - The Percutaneous Absorption-Type Analgesic and Anti-inflammatory Drug Loxonin(R)Tape 50mg/100mg
-
- Analytical Results for Women from Large Scale Clinical Trial MEGA Study Employing the Hypercholesterolemia Drug Mevalotin(R) Published
-
- Broad-spectrum Oral Antibacterial Agent
Gracevit(R) tablets 50mg/fine granules 10%
Receives Approval for Manufacturing and Marketing - Broad-spectrum Oral Antibacterial Agent
2007
-
- Application Filed for Additional Indication for Selective Antithrombin Agents Novastan(R) HI Injection 10mg/2mL and Slonnon(R) HI Injection 10mg/2mL for Heparin-Induced Thrombocytopenia
-
- Additional Pediatric Indication for Fentanyl Injection Approved
Japan's First Ever Approval of Physician-led Clinical Trial - Additional Pediatric Indication for Fentanyl Injection Approved
-
- Amgen Grants Daiichi Sankyo Exclusive Rights to Develop and
Commercialize Denosumab in Japan - Amgen Grants Daiichi Sankyo Exclusive Rights to Develop and
-
- Amlodipine and Olmesartan Study Results Released;
Late Breaker Presented at American Society of Hypertension
Twenty-Second Annual Scientific Meeting (ASH 2007)
First Release of Data for New Combination
- Amlodipine and Olmesartan Study Results Released;
-
- Launch of New Package (0.8-g sachet) of Zyrtec(R) Dry Syrup 1.25% selective H1 receptor antagonist,anti-allergic agent
-
- DAIICHI SANKYO, INC. ANNOUNCES FILING OF SUPPLEMENTAL NEW DRUG APPLICATION FOR WELCHOL IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS
2006
-
- DAIICHI SANKYO, INC. ANNOUNCES FILING OF NEW DRUG APPLICATION FOR AMLODIPINE BESYLATE / OLMESARTAN MEDOXOMIL COMBINATION FOR THE TREATMENT OF HYPERTENSION
-
- DAIICHI SANKYO Subsidiary Files for Additional Pediatric Indication for Fentanyl Injection
-
- SANKYO COMMENCES PATENT LITIGATION AGAINST BENICAR® ANDA FILING IN THE UNITED STATES
-
- Launch of New Formulation Zyrtec® Dry Syrup 1.25%
selective H1 receptor antagonist, anti-allergic agent - Launch of New Formulation Zyrtec® Dry Syrup 1.25%
-
- Percutaneous Absorption-Type Analgesic and Anti-inflammatory Drug
Loxonin Poultice 100mg to Go on Sale - Percutaneous Absorption-Type Analgesic and Anti-inflammatory Drug
2005
